NCT04266145View on ClinicalTrials.gov

Intravenous Versus Perineural Dexmedetomidine as Adjuvant in Adductor Canal Block for Total Knee Arthroplasty

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 29, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

August 25, 2022

Conditions
Post Spinal Anesthesia Shivering
Interventions
DRUG

intravenous dexmedetomidine

adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline

DRUG

adductor canal block dexmedetomidine

adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline

Trial Locations (1)

Unknown

Mansoura University Hospitals, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04266145 - Intravenous Versus Perineural Dexmedetomidine as Adjuvant in Adductor Canal Block for Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter